百欧海文制药
BHVN
10.78
-0.65
-5.69%
百欧海文制药
US · BHVN
#2805 按市值排名
上市于 2017
10.78
-0.65
-5.69%
实时 - 追踪5344个代码 - 心跳于6秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例上升了0.7个百分点。
机构持股
- 机构持股比例
- 94.74% +0.74pp
- 机构数量
- 339 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund48.06%
Hedge Fund35.23%
Individual/Insider10.94%
Private Company3.91%
Public Company3.83%
VC/PE Fund2.00%
Insurance Company0.90%
Government Pension Fund0.47%
Family Office/Trust0.33%
主要股东 截至 2026-06-30
BlackRock
8.75% · 13.21M 股
Montanova Capital, LLC
6.81% · 10.29M 股
Stifel Asset Management Corp.
6.58% · 9.94M 股
John Childs
6.54% · 9.88M 股
Janus Henderson Group plc
5.68% · 8.58M 股
Woodline Partners LP
5.07% · 7.66M 股
State Street Global Advisors
4.60% · 6.95M 股
Infinitum Asset Management, LLC
4.14% · 6.25M 股
D. E. Shaw & Co., L.P.
2.77% · 4.19M 股
AQR Capital Management
2.70% · 4.08M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 37次买入 · 9次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| John Childs | Independent Director | 6.54% |
| Vladimir Coric | Chairperson & CEO | 2.55% |
| Gregory Bailey | Independent Director | 1.34% |
| Warren Volles | General Counsel & Chief Legal Officer | 0.16% |
| Matthew Buten | Chief Financial Officer | 0.13% |
| Kimberly Gentile | Senior Vice President of Clinical Operations | 0.07% |
| George Clark | Vice President | 0.06% |
| Bruce Car | Chief Scientific Officer | 0.04% |
| Julia Gregory | Independent Director | 0.02% |
| Kishan Mehta | Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +1,000 | $12.34 |
| 2026-08-05 | Infinitum Asset Management, LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-07-08 | Warren Volles | General Counsel & Chief Legal Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-27 | John Childs | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Julia Gregory | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Robert Hugin | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Gregory Bailey | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Michael Heffernan | Lead Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Irina Antonijevic | Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Kishan Mehta | Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-03-16 | Kishan Mehta | Director | Other Acquisition | +17,342 | -- |
| 2026-03-16 | Kishan Mehta | Director | Other Disposition | -17,342 | -- |
| 2026-02-26 | Matthew Buten | Chief Financial Officer | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | Vladimir Coric | Chairperson & CEO | Other Derivative Acquisition | +550,000 | $11.52 |
| 2026-02-26 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | Bruce Car | Chief Scientific Officer | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | George Clark | Vice President | Other Derivative Acquisition | +50,000 | $11.52 |
| 2026-01-04 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Sale | -2,594 | $9.93 |
| 2026-01-04 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Retained | +1,656 | -- |
| 2026-01-04 | Vladimir Coric | Chairperson & CEO | Derivative Exercise and Sale | -7,430 | $9.93 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
百欧海文制药 讨论区 0 条评论